Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Singer

Showing results (551-560 of 649) with videos related to

Pageof 65
Sort By:
The New England Journal of Medicine|July 28, 2021
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast CancerMichael Gnant, Florian Fitzal, Gabriel Rinnerthaler, et al.
Cancer Research|July 9, 2009
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriersTimothy R Rebbeck, Nandita Mitra, Susan M Domchek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast CancerSherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Breast Cancer Research : BCR|January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])A DeMichele, A C Dueck, D Hlauschek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersBrian S Finkelman, Wendy S Rubinstein, Sue Friedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2024
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i>Kelly-Anne Phillips, Joanne Kotsopoulos, Susan M Domchek, et al.
Journal of the National Cancer Institute|June 27, 2023
Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiationMark van Barele, Delal Akdeniz, Bernadette A M Heemskerk-Gerritsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
Breast Cancer Research and Treatment|April 28, 2016
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriersDana Madorsky-Feldman, Miri Sklair-Levy, Tamar Perri, et al.
Breast Cancer Research and Treatment|September 27, 2012
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriersKristen N Stevens, Xianshu Wang, Zachary Fredericksen, et al.
Pageof 65

Showing results (551-560 of 649) with videos related to

Sort By:
Pageof 65
The New England Journal of Medicine|July 28, 2021
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast CancerMichael Gnant, Florian Fitzal, Gabriel Rinnerthaler, et al.
Cancer Research|July 9, 2009
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriersTimothy R Rebbeck, Nandita Mitra, Susan M Domchek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast CancerSherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Breast Cancer Research : BCR|January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])A DeMichele, A C Dueck, D Hlauschek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersBrian S Finkelman, Wendy S Rubinstein, Sue Friedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2024
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i>Kelly-Anne Phillips, Joanne Kotsopoulos, Susan M Domchek, et al.
Journal of the National Cancer Institute|June 27, 2023
Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiationMark van Barele, Delal Akdeniz, Bernadette A M Heemskerk-Gerritsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
Breast Cancer Research and Treatment|April 28, 2016
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriersDana Madorsky-Feldman, Miri Sklair-Levy, Tamar Perri, et al.
Breast Cancer Research and Treatment|September 27, 2012
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriersKristen N Stevens, Xianshu Wang, Zachary Fredericksen, et al.
Pageof 65